Outlook Therapeutics, Inc. (OTLK)
0.5617
-0.01
(-2.18%)
USD |
NASDAQ |
Jan 13, 16:00
0.5617
0.00 (0.00%)
After-Hours: 17:38
Outlook Therapeutics Research and Development Expense (Annual): 27.78M for Sept. 30, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 109.41M |
| Amicus Therapeutics, Inc. | 109.36M |
| Neogen Corp. | 21.09M |
| CorMedix, Inc. | 3.942M |
| NovaBay Pharmaceuticals, Inc. | 0.042M |